Novel pipeline therapies to drive diabetic neuropathic pain market across 7MM to $3 bn in 2031: GlobalData

The diabetic neuropathic pain (DNP) market across the seven major markets (7MM*) is poised to grow at a compound annual growth rate (CAGR) of 6.0 per cent from $1.7 billion in 2021 to $3.0 billion in 2031, driven by the potential introduction of four promising late-stage pipeline products and an increase in the prevalent patient population, forecasts GlobalData.

Christie Wong, Pharma Analyst at GlobalData, explains, “The diabetic neuropathic pain market is crowded with inexpensive generic oral analgesics such as tricyclic antidepressants, serotonin-noradrenaline reuptake inhibitors, gabapentinoids, and sodium channel blockers. These are unlikely to be replaced as first line oral analgesics. However, the prospect of novel pipeline therapies will be welcomed as they target an underserved population of patients who do not respond adequately to current therapies.”

GlobalData’s report, “Diabetic Neuropathic Pain Market Size and Trend Report, reveals that four pipeline therapies—Helixmith’s  Engensis (VM202), Glenmark Pharmaceutical’s ISC-17536, Lexicon Pharmaceuticals’ LX-9211, and Novaremed’s NRD135SE.1 (NRD.E1)—will enter the diabetic neuropathic pain market and are expected to represent 48.3 per cent of the market in 2031, equivalent to about $1.5 billion.

Wong adds, “Due to the potential disease-modifying properties of Engensis, it is anticipated to become the top-selling drug in the diabetic neuropathic pain market. Engensis is forecast to launch in the US in 2025 and generate sales of $679.6 million by 2031.”

Although the diabetic neuropathic pain market is projected to grow in the 7MM during the forecast period, limited growth is anticipated in the 5EU** and Japan. ISC-17536 is the only late-stage pipeline product set to launch in the 5EU. Furthermore, none of the four late-stage pipeline products are anticipated to launch in Japan by 2031.

Wong concludes, “The US will remain as a dominant market throughout the forecast period. The launch of four pipeline products in the US prior to 2031 will create more treatment options for patients and address some of the unmet needs in the diabetic neuropathic pain market to varying extents. As a result, considerable opportunity remains for players looking to enter the market in the future, particularly outside of the US.”

*7MM: US, France, Germany, Italy, Spain, the UK, and Japan

**5EU: France, Germany, Italy, Spain, the UK